Friday 6 November 2026 Export PCVX’s income statement to Excel — free account

Vaxcyte, Inc.

PCVX Healthcare Biotechnology

EPS: −27.9%
Free cash flow: −92.6%

Quarter to September 2026, against a year earlier

63.82 1.90 +3.07%

Follow PCVX

Alert me

Market cap: $9.8B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Vaxcyte, Inc. 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 4, 2026 · accepted 4:18 PM ET · Document on sec.gov · Filing index

Red flags

Short cash runway Nov 4, 2026
Vaxcyte, Inc.’s cash and short-term investments cover about 0.5 quarters of its operating cash burn

10-Q filed Nov 4, 2026 · The filing · sec.gov
Share dilution Nov 4, 2026
Shares outstanding rose 20.9% in a year, to 158.3 million

10-Q filed Nov 4, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 5, 2026: 20 added · 3 removed · 79 modified; 2 with only figures updated